Intelligent Bio Solutions Stock (NASDAQ: INBS)

Dernières nouvelles pour Intelligent Bio Solutions (NASDAQ:INBS) Stock

Intelligent Bio Solutions

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).

Vertiv Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) announced Thursday that it has <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44943886/vertiv-reports-strong-first-quarter-2025-results" rel="noreferrer noopener">agreed to acquire</a> Great Lakes Data Racks &amp; Cabinets for $200 million, a move designed to strengthen its leadership in the expanding AI and edge computing markets. The transaction is expected to close in the third quarter of 2025.
This acquisition will enhance Vertiv&#8217;s ability to deliver pre-engineered, AI-ready rack solutions for data centers, enterprise, edge, and hyperscale computing markets.
Great Lakes, established in 1985, operates manufacturing facilities in the U.S. and Europe. It specializes in customizable data racks, seismic cabinets, and cable management solutions.
Also Read: <a href="https://www.benzinga.com/markets/tech/25/06/45982049/vertiv-holdings-stock-25-off-highs-is-now-riding-nvidias-ai-wave" target="_blank" rel="noreferrer noopener">Vertiv Holdings Stock, 25% Off Highs, Is Now Riding Nvidia&#8217;s AI Wave</a>
Vertiv&#8217;s CEO, Gio Albertazzi, noted that this deal will not only streamline sourcing and improve operational efficiency but also increase scalability for AI and edge computing applications. He emphasized, &#8220;Great Lakes strengthens Vertiv&#8217;s position as a premier technology solutions provider in the AI infrastructure environment.&#8221;
By integrating Great Lakes&#8217; expertise, Vertiv will be able to offer faster deployment, more efficient sourcing, and enhanced solutions for critical digital infrastructure. The acquisition is also expected to generate significant cost synergies and cross-selling opportunities.
The deal is still subject to regulatory approvals under the Hart-Scott-Rodino Antitrust Improvements Act. Vertiv held cash and cash equivalents of <a href="https://www.benzinga.com/pressreleases/25/04/n44943886/vertiv-reports-strong-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">$1.467 billion</a> as of March 31, 2025.
Price Action: VRT shares are trading higher by 4.78% to $131.39 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46463102/amazons-bedrock-agentcore-platform-hints-at-future-of-work-ai-agents-that-think-code-and-collaborate" target="_blank" rel="noreferrer noopener">Amazon&#8217;s Bedrock AgentCore Platform Hints At Future Of Work: AI Agents That Think, Code And Collaborate</a></li>
</ul>
Photo via Shutterstock

News

Movers

Tech

Vertiv Buys Rack Solutions Provider To Enhance AI Infrastructure

Bank OZK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OZK#NASDAQ">OZK</a>) will release earnings results for the second quarter, after the closing bell on <a href="https://www.benzinga.com/quote/OZK/earnings">Thursday, July 17</a>.
Analysts expect the Little Rock, Arkansas-based company to report quarterly earnings at $1.52 per share, versus $1.52 per share in the year-ago period. Bank OZK projects to report quarterly revenue at $423.41 million, compared to $416.78 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 1, Bank OZK announced an increase to its quarterly common stock dividend from 43 cents to 44 cents per share.
Bank OZK shares gained 0.9% to close at $51.17 on Wednesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/WBA/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Wells Fargo analyst Timur Braziler maintained an Equal-Weight rating and raised the price target from $40 to $48 on July 10, 2025. This analyst has an accuracy rate of 64%.</li>
<li>Raymond James analyst Daniel Tamayo upgraded the stock from Market Perform to Outperform with a price target of $58 on July 8, 2025. This analyst has an accuracy rate of 62%.</li>
<li>Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintained a Market Perform rating and cut the price target from $50 to $48 on April 22, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Stephens &amp; Co. analyst Matt Olney maintained an Equal-Weight rating and cut the price target from $59 to $54 on April 21, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Morgan Stanley analyst Manan Gosalia maintained an Equal-Weight rating and cut the price target from $58 to $54 on March 13, 2025. This analyst has an accuracy rate of 76%.</li>
</ul>
Considering buying OZK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/ozk/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="579" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/17040344/image-210-1024x579.png" alt="" class="wp-image-989173" style="width:635px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/17040344/image-210-1024x579.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/17040344/image-210-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/17040344/image-210-768x435.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/17040344/image-210.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> J<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46439944/jim-cramer-takes-a-pass-on-this-money-losing-utilities-stock">im Cramer &#8216;Takes A Pass&#8217; On This Money-Losing Utilities Stock</a></li>
</ul>
Photo via Shutterstock

Earnings

Price Target

Markets

Analyst Ratings

Trading Ideas

Bank OZK Likely To Report Higher Q2 Revenue; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Barclays analyst Christine Cho maintains Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) with a Equal-Weight and raises the price target from $5 to $9.

FLNC

Barclays Maintains Equal-Weight on Fluence Energy, Raises Price Target to $9

<a href="https://www.bloomberg.com/news/articles/2025-07-17/eni-deal-with-blackrock-s-gip-said-to-value-carbon-unit-at-1-billion?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-07-17/eni-deal-with-blackrock-s-gip-said-to-value-carbon-unit-at-1-billion?embedded-checkout=true</a>

General

'Eni Deal With BlackRock's GIP Said to Value Carbon Unit at €1 Billion'- Bloomberg

Barclays analyst Dan Levy maintains First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) with a Overweight and raises the price target from $20 to $21.

FWRG

Barclays Maintains Overweight on First Watch Restaurant Gr, Raises Price Target to $21

<a href="https://techcrunch.com/2025/07/17/spotify-expands-audiobook-access-to-family-plan-members-for-the-first-time/">https://techcrunch.com/2025/07/17/spotify-expands-audiobook-access-to-family-plan-members-for-the-first-time/</a>

SPOT

'Spotify expands audiobook access to family plan members for the first time'- Techcrunch

Barclays analyst Jeffrey Bernstein maintains Dutch Bros (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) with a Overweight and raises the price target from $82 to $84.

BROS

Barclays Maintains Overweight on Dutch Bros, Raises Price Target to $84

Shares of electric vehicle maker Volcon Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) are trading sharply higher Thursday morning after the company revealed it has secured over $500 million in a <a href="https://www.benzinga.com/pressreleases/25/07/ac46465459/volcon-announces-over-500-000-000-private-placement-to-initiate-bitcoin-treasury-strategy">private placement</a> and will pivot its corporate treasury strategy to focus on Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>).
What To Know: Volcon entered into agreements with institutional investors to sell approximately 50.1 million shares of common stock at $10.00 per share. The financing was led by Empery Asset Management and saw participation from prominent crypto venture firms, including FalcolnX, Pantera and Borderless.
In a major strategic shift, Volcon <a href="https://www.benzinga.com/pressreleases/25/07/ac46465459/volcon-announces-over-500-000-000-private-placement-to-initiate-bitcoin-treasury-strategy">intends</a> to use at least 95% of the gross proceeds to acquire Bitcoin, establishing the cryptocurrency as its primary treasury reserve asset. &#8220;In an era of accelerating monetary debasement, holding Bitcoin on our balance sheet represents a strategic move to safeguard shareholder value,&#8221; stated co-CEO John Kim.
To execute this plan, Volcon has partnered with Gemini Nustar LLC for digital asset services and appointed four new members to its board of directors, including Ryan Lane from lead investor Empery. The private placement, with Clear Street LLC as lead placement agent, is expected to close on or about July 21.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, VLCN shares are trading higher by 246.2% to $33.63 Thursday morning. The stock has a 52-week high of $218.88 and a 52-week low of $4.40.
Read Also: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46465098/bitcoin-holds-steady-as-ethereum-xrp-dogecoin-push-higher">Bitcoin Holds Steady As Ethereum, XRP, Dogecoin Push Higher</a>
<h2 class="wp-block-heading">How To Buy VLCN Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Volcon&#8217;s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

$BTC

VLCN

Volcon (VLCN) Stock Soars On $500M Funding And Strategic Pivot To Bitcoin

Barclays analyst Jeffrey Bernstein maintains Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Equal-Weight and raises the price target from $54 to $55.

Barclays Maintains Equal-Weight on Chipotle Mexican Grill, Raises Price Target to $55

Barclays analyst Jeffrey Bernstein maintains Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) with a Equal-Weight and raises the price target from $90 to $91.

CAVA

Barclays Maintains Equal-Weight on Cava Group, Raises Price Target to $91

Snap-On Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNA#NYSE">SNA</a>) reported better-than-expected <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46462469/snap-on-announces-second-quarter-2025-results" rel="noreferrer noopener">second-quarter 2025 results</a>, surpassing both revenue and earnings consensus estimates.
Here's a breakdown of the report:
<ul class="wp-block-list">
<li>Quarterly net sales reached $1.179 billion flat year-over-year increase and above the consensus estimate of $1.16 billion.</li>
<li>Sales reflected a $8.6 million, or 0.7%, organic decline, which was counterbalanced by an $8.6 million gain from favorable foreign currency translation.</li>
<li>The gross margin contracted by 15 bps to 50.5%, and gross profit fell 0.30% year over year to $595.5 million.</li>
<li>Financial services revenue rose to $101.7 million (+1.2% YoY), with operating earnings at $68.2 million, up from $70.2 million, respectively, in 2024.</li>
<li>Consolidated operating earnings for the quarter were $327.3 million, or 25.5% of revenues, down from $350.5 million, or 27.4%, in 2024.</li>
<li>EPS for the quarter was $4.72, down from $5.07 YoY, above the consensus of $4.67.</li>
<li>Operating cash flow for the quarter totaled $ 237.2 million, compared to $ 301.1 million a year ago, with $1.458 billion in cash and equivalents at the quarter's end.</li>
</ul>
Snap-on CEO Nick Pinchuk noted that the sales growth in the U.S. Tools Group, along with &#8220;solid operating earnings performance,&#8221; was achieved despite the headwinds of &#8220;general uncertainty and trade turbulence.&#8221;
Also Read: <a href="https://www.benzinga.com/m-a/25/06/45769775/chart-industries-and-flowserve-announce-19-billion-merger-eyes-300-million-in-synergies" target="_blank" rel="noreferrer noopener">Chart Industries And Flowserve Announce $19 Billion Merger, Eyes $300 Million In Synergies</a>
Sales by segments:
<ul class="wp-block-list">
<li>Commercial &amp; Industrial $347.8 million (-7.6% YoY), Operating earnings were $46.9 million, with a margin of 13.5%, down from 16.7% last year.</li>
<li>Snap-on Tools $491 million (+1.6% YoY), driven by U.S. sales growth. Operating earnings were $116.7 million, with a stable margin of 23.8%.</li>
<li>Repair Systems &amp; Information $468.6 million (+2.3% YoY), driven by higher OEM dealership activity and increased sales of diagnostic products. Operating earnings were $119.8 million, with a margin of 25.6%, up from 25.0% last year.</li>
</ul>
Outlook 2025: Snap-on expects continued growth in 2025, expanding its professional customer base in automotive repair and adjacent markets, with projected capital expenditures of $100 million.
The company anticipates a full-year 2025 effective income tax rate between 22% and 23%.
Price Action: Snap-on shares are trading higher by 2.87% at $322 premarket at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46464911/delta-air-lines-to-pay-8-1-million-to-settle-doj-probe-over-alleged-misuse-of-pandemic-relief-funds" target="_blank" rel="noreferrer noopener">Delta Air Lines To Pay $8.1 Million To Settle DOJ Probe Over Alleged Misuse Of Pandemic Relief Funds</a></li>
</ul>
Image: Shutterstock

Snap-On Tools Segment Drives Growth While Margins Tighten In Q2 Beat

Barclays analyst Jeffrey Bernstein maintains Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) with a Equal-Weight and raises the price target from $155 to $166.

Barclays Maintains Equal-Weight on Brinker International, Raises Price Target to $166

WIIM

HBIO

Harvard Bioscience shares are trading higher after the company announced the appointment of John Duke as CEO. Also the company reaffirmed its Q2 revenue guidance and margin guidance.

Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) shares are trading higher Thursday after the company, along wither Uber and Nuro, announced a global robotaxi program developed for the Uber (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) <a href="https://www.benzinga.com/node/46464961">ride-hailing platform</a>.
What To Know: The companies unveiled a next-generation premium robotaxi service built on the Lucid Gravity SUV, powered by Nuro's Level 4 autonomy system, and deployed through the Uber platform. The service is set to launch in a major U.S. city next year, with plans to scale to 20,000 or more autonomous vehicles across dozens of global markets over six years.
Vehicles will be manufactured by Lucid with integrated autonomous hardware and later commissioned by Uber, receiving Nuro's AI-powered self-driving software. The robotaxis will be operated by Uber or third-party fleet partners and offered exclusively on Uber's app.
Uber also plans to make multi-hundred-million-dollar investments in both Lucid and Nuro as part of the partnership.
Lucid's Interim CEO Marc Winterhoff said the deal validates the company's technology as ideal for autonomous ridesharing, citing its range, spacious interiors and fully redundant zonal architecture. The Gravity's 450-mile estimated range is expected to support high asset utilization and minimal downtime.
Nuro will lead safety development through simulation, closed-course testing, and supervised on-road trials. The prototype robotaxi is already being tested autonomously at Nuro's Las Vegas proving grounds.
Uber CEO Dara Khosrowshahi called the partnership a step toward bringing autonomous mobility to millions, while Nuro Co-Founder and CEO Jiajun Zhu said the collaboration reflects the potential of combining proven autonomy with global scale.
See Also: <a href="https://www.benzinga.com/markets/earnings/25/07/46466924/ge-aerospace-lifts-2025-outlook-on-soaring-orders-profits-and-cash-flow">GE Aerospace Lifts 2025 Outlook On Soaring Orders, Profits, And Cash Flow</a>
LCID Price Action: At the time of writing, Lucid stock is trading 31.4% higher at $3.02, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Image via Shutterstock

LCID

UBER

Lucid Stock Is Trading Higher Thursday: What's Going On?

Barclays analyst Jeffrey Bernstein maintains Bloomin Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMN#NASDAQ">BLMN</a>) with a Equal-Weight and raises the price target from $8 to $9.

BLMN

Barclays Maintains Equal-Weight on Bloomin Brands, Raises Price Target to $9

SGRP

SPAR Group shares are trading higher. The company reported Q1 financial results.

Barclays analyst Jeffrey Bernstein maintains BJ's Restaurants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>) with a Underweight and raises the price target from $33 to $37.

BJRI

Barclays Maintains Underweight on BJ's Restaurants, Raises Price Target to $37

DFDV

DFDV stock has given up its prior gain. DeFi Development shares were trading higher after the company announced it has launched a franchise model to support its global Solana treasury vehicles.

Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported better-than-expected sales and profits in the second quarter, but the stock still plummeted nearly 10% after management dialed back earnings and growth projections for the rest of the year.
The company reported second-quarter sales of $11.14 billion, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $11.07 billion</a>.
Second-quarter sales increased 7.4% on a reported basis, 6.9% on an organic basis, or 7.5% when excluding COVID-19 testing-related sales.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/earnings/25/07/46468951/elevance-health-hit-by-medicaid-troubles-trims-outlook" rel="noreferrer noopener">Elevance Health Hit By Medicaid Troubles, Trims Outlook</a>
The U.S. MedTech giant reported adjusted earnings of $1.26, beating the consensus of $1.25, and within the management <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44838946/abbott-labs-clocks-q1-profit-beat-ceo-says-diversification-and-execution-enable-navigation-during-uncertainty" rel="noreferrer noopener">guidance of $1.23-$1.27</a>.
&#8220;Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline,&#8221; said Robert B. Ford, chairman and chief executive officer, Abbott. &#8220;We see this momentum carrying into 2026.&#8221;
Medical Devices sales increased 13.4% on a reported basis and 12.2% on an organic basis to $5.37 billion.
Sales growth in the quarter was led by double-digit growth in Diabetes Care, Heart Failure, Structural Heart, and Electrophysiology.
Several products contributed to the performance, including FreeStyle Libre, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46463570/abbott-reports-second-quarter-2025-results" rel="noreferrer noopener">Navitor, TriClip, and AVEIR</a>.
In Diabetes Care, sales of continuous glucose monitors were $1.9 billion and grew 21.4% on a reported basis and 19.6% organically.&nbsp;
Worldwide Nutrition sales increased 2.9% (+3.4% on an organic basis) to $2.21 billion.
Growth in the quarter was led by Adult Nutrition, where global sales increased 6.1% (+6.6% on an organic basis), led by strong growth of Ensure and Glucerna.
Global Diagnostics sales decreased 1% (-1.4% on an organic basis) and increased 0.8% when excluding COVID-19 testing-related sales.
The year-over-year decline in COVID-19 testing-related sales and volume-based procurement programs in China impacted diagnostics sales growth.
COVID-19 testing-related sales were $55 million in the quarter, compared to $102 million a year ago.
Established Pharmaceuticals sales increased 6.9% (+7.7% on an organic basis) to $1.38 billion.
Abbott&#8217;s reported operating margin of 18.4%, with an adjusted operating margin of 22.9%, which reflects a 100 basis point increase.
<h2 class="wp-block-heading">Guidance</h2>
Abbott narrowed full-year 2025 adjusted earnings guidance from $5.05-$5.25 per share to $5.10-$5.20 per share compared to the consensus of $5.16.
The company expects organic sales growth of 7.5%-8.0% compared to prior guidance of 7.5%-8.5%, or 6.0% to 7.0% when including COVID-19 testing-related sales.
Abbott forecasts an adjusted operating margin of approximately 23.5% of sales, down from prior guidance of 23.5%- 24.0%.
Abbott expected third-quarter 2025 adjusted earnings of $1.28-$1.32 per share, compared to the consensus of $1.34 per share.
During the earnings conference call, an Abbott executive addressed the impact of tariffs, reporting that the estimated headwind has been revised down to $200 million for the year, lower than previous estimates.&nbsp;
Price Action:&nbsp;ABT stock is trading lower by 8.00% to $121.21&nbsp;at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46465321/novartis-trims-operating-income-outlook-after-strong-q2-performance-initiates-10-billion-stock-buyback" target="_blank" rel="noreferrer noopener">Novartis Trims Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback</a></li>
</ul>
Photo via Shutterstock

Large Cap

Guidance

Health Care

Eased Tariff Impact Fails To Lift Abbott As Outlook Cut Disappoints Investors

As the corporate services sector continues to navigate a landscape of cautious optimism, Cintas Corporation&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) recent earnings report highlights a critical shift in investor sentiment. <a href="https://www.benzinga.com/earnings">Despite surpassing earnings</a> and sales expectations, the company&#8217;s stock dipped.
Cintas shares are trading<a href="https://www.benzinga.com/pressreleases/25/07/b46464958/cintas-corporation-announces-fiscal-2025-fourth-quarter-and-full-year-results" target="_blank" rel="noreferrer noopener"> lower on Thursday</a> after the company reported fourth-quarter earnings per share of $1.09, beating the analyst consensus estimate $1.07.
Quarterly sales of $2.667 billion (+8% year over year) outpaced the Street view of $2.626 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/macro-economic-events/25/07/46467952/us-retail-sales-june-2025-fed-trump-inflation-consumer" rel="noreferrer noopener">US Shoppers Keep Spending, Sending A Loud Message To Powell And Trump</a>
The fourth quarter of fiscal 2025 was negatively impacted by one fewer workday compared to the fourth quarter of fiscal 2024.
Gross profit increased to $1.33 billion compared to $1.22 billion in last year&#8217;s fourth quarter, an increase of 9.1%.&nbsp;
Gross margin was 49.7% compared to 49.2% in last year&#8217;s fourth quarter, an increase of 50 basis points.
Operating income for the fourth quarter of fiscal 2025 rose 9.1% to $597.5 million, with a margin of 22.4% versus 22.2% in the prior-year quarter.
&#8220;As we enter fiscal 2026, we remain focused on delivering unmatched service to our customers, leveraging our distinctive culture and generating sustainable, long-term results for all our stakeholders,&#8221; said the company&#8217;s CEO Todd M. Schneider.
The company exited the quarter with cash and equivalents totaling $263.97 million and inventories valued at $447.408 million.
Outlook: Cintas expects fiscal 2026 GAAP EPS to range between $4.71 and $4.85, compared to the $4.84 consensus estimate.
The company projects revenue between $11.00 billion and $11.15 billion, compared to the $11.04 billion estimate.
CTAS Price Action: Cintas shares were up 0.45% at $214.98 at the time of publication Thursday, <a href="https://www.benzinga.com/pro/" target="_blank" rel="noreferrer noopener">according to Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46466114/u-s-bancorp-nails-q2-profits-but-stock-dips-on-revenue-miss" target="_blank" rel="noreferrer noopener">U.S. Bancorp Nails Q2 Profits But Stock Dips On Revenue Miss</a></li>
</ul>
Photo: Shutterstock

Equities

CTAS

What's Going On With Cintas Corporation Stock Today?

Press Releases

Intelligent Bio Solutions Accelerates Global Adoption of Fingerprint Drug Testing

Intelligent Bio Solutions Showcases Rapid, Non-Invasive Drug Testing Capabilities in Remote Queensland Workforce Deployment

Intelligent Bio Solutions to Showcase Fingerprint Drug Testing at RISE25 Conference from May 28-31, Supporting Innovation in U.S. Forensic Drug Testing

Intelligent Bio Solutions Expands U.S. Forensic Market Presence, Seeks FDA Clearance for Breakthrough Fingerprint Drug Testing

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Harry Simeonidis, President and CEO of Intelligent Bio Solutions Inc.

Contracts

Intelligent Bio Solutions Launches In-House Fingerprint Drug Testing Across 20+ Sites for Major Australian Waste Operator, Accelerating APAC Expansion

Intelligent Bio Solutions and Spjotgard Drive Rapid Adoption of Fingerprint Drug Testing Across Scandinavia

Intelligent Bio Solutions to Present PK Study Data at Association for Diagnostics and Laboratory Medicine 2025 Clinical Lab Expo

Intelligent Bio Solutions Adds Next-Gen Wearable for Extended Drug Detection to Product Offering, Strengthening Leadership in Non-Invasive Testing

Intelligent Bio Solutions Accelerates Global Growth with SmarTest® Patch Agreement, Reinforces U.S. Expansion Path as FDA Approval Remains a Strategic Priority

Comments

Intelligent Bio Solutions

Actualités

Dernières nouvelles pour Intelligent Bio Solutions (NASDAQ:INBS) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL